Belite Bio, Inc
BLTENASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $5.92B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $88.00$200.00
- Volume (live)
- -
- Avg. volume (3M)
- 146.43K
Belite Bio (BLTE) Stock Price & Financial Analysis
Belite Bio Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $146.27 - $150.70 |
|---|---|
| 52-Week High | $200.00 |
| 52-Week Low | $88.00 |
| Open | $150.70 |
| Volume (last close) | 49.85K |
| Average Volume (3M) | 146.43K |
| 50-Day MA | $164.44 |
|---|---|
| 200-Day MA | $160.75 |
| 1-Year Change | +62.95% |
| Market Cap | 5.92B |
|---|---|
| Shares Outstanding | 40.18M |
| Price to Book (P/B) | 7.62 |
| EV/EBITDA | -53.93 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Belite Bio at a Glance
As of the Oct 23, 2026 close, Belite Bio (BLTE) has a market capitalization of $5.92B.
As of its latest reported balance sheet, it holds $0.00 in cash and securities against $0.00 of debt, a net cash position of $0.00.
Belite Bio does not currently pay a dividend.
The share price is up 62.9% over the past year. At $147.33 (the Oct 23, 2026 close) it sits within its 52-week range of $88.00 to $200.00, below its 200-day moving average of $160.75.
Based on 8 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $236.86, 60.8% above the Oct 23, 2026 close.
Frequently Asked Questions About Belite Bio
What is the current stock price for BLTE?
As of the Oct 23, 2026 close, BLTE stock trades at $147.33. The 52-week range is $88.00–$200.00, with a day range of $146.27–$150.70.
What is the P/E ratio for BLTE?
The P/E ratio (Price-to-Earnings) for BLTE is shown in the Key Statistics section. This valuation metric helps compare Belite Bio, Inc to industry peers.
Does BLTE pay dividends?
Belite Bio does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for BLTE?
Based on ratings from 8 professional analysts over the last 90 days, the consensus for BLTE is Buy. The average 12-month price target is $236.86, a 60.8% upside from the Oct 23, 2026 close of $147.33.
What is the market cap of BLTE?
As of the Oct 23, 2026 close, Belite Bio's market capitalization is $5.92B, classifying it as a mid-cap company. Belite Bio operates in the Healthcare sector within the Biotechnology industry.